AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$TENX

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.8M of TENX (indirect holdings)

ADAR1 Capital Management, LLC purchased 1,025,867 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.77 ($1.75–$1.78, $1.81M total) across 3 trades over 2026-08-20 to 2026-08-24. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting
SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel
Published Aug 24, 2026, 10:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TENX
Bullish
medium confidence
Mentioned
$TENX
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TENXBullishLow
01

Why it matters

The purchase adds to insider confidence but limited in scale.

02

Market read

Insider buying may provide a modest bullish cue for TENX traders.

03

What to watch

The purchase size is small relative to market cap; broader market conditions may dominate price movement.

Relevance 7/10Novelty 7/10Timing: filed today

Background

SEC Form 4 filing reveals insider transaction for Tenax Therapeutics.

Company-level read

Ticker impact

$TENXBullishMedium confidence
Context

Form 4 disclosed ADAR1 Capital Management purchased 1.03M shares of Tenax Therapeutics for $1.8M, increasing its stake to 4.85M shares.

Expected impact

Potential modest price lift in the near term.

Evidence & confidence

10% owner increased holdings by $1.8M; while amount is modest, insider stake signals bullish sentiment.

Market effects

Sector

May indicate confidence in biotech sector pipeline.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong signal.

Key entities

  • Company
    Tenax Therapeutics, Inc.

    Biopharmaceutical company listed on NASDAQ.

  • Investor
    ADAR1 Capital Management, LLC

    Investment manager and 10% owner of Tenax.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TENX insider trading history →

Related articles

AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min
AUG 11
$TENXHighAI 9/10

Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF

Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.

thepharmaletter.com2 min
AUG 11
$TENXMed

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax reported its Phase III LEVEL trial of oral levosimendan missed the primary endpoint. The six-minute walk improvement versus placebo was 3.5 meters but not statistically significant, and the quality-of-life endpoint also failed. Subgroup and biomarker results suggested larger benefits in higher-risk patients. Tenax will consult the FDA and EMA and may adjust LEVEL-2 or run a new study.

yahoo.com2 min
AUG 10
$METAMed

Futures Erase Overnight Gains As Oil Hits One-Week High, Yen Slides

US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.

zerohedge.com7 min
AUG 10
$TENXHighAI 8/10

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.

investing.com7 min